Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 7;23(1):e0129.
doi: 10.1097/CLD.0000000000000129. eCollection 2024 Jan-Jun.

Proper assessment and prognostication of patients with hepatocellular carcinoma

Edoardo G Giannini  1   2
Affiliations
Review

Proper assessment and prognostication of patients with hepatocellular carcinoma

Edoardo G Giannini. Clin Liver Dis (Hoboken). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Edoardo G. Giannini advises and is on the speakers’ bureau for Roche and MSD-Eisai. He advises AstraZeneca. He consults for GSK.

Figures

FIGURE 1
FIGURE 1
Trends of population attributable fraction of principal etiologic factors for HCC, with reasons for the observed modifications.
FIGURE 2
FIGURE 2
The concept of multiparametric therapeutic hierarchy guiding treatment options in patients with HCC. *Extrahepatic metastases, invasion of the main trunk of the portal vein or inferior vena cava. †Mini-invasive approach offers a prognostic advantage (decreased risk of postoperative liver failure) and decreases the impact of liver dysfunction by one cross. Reprinted with permission from Vitale et al. Abbreviations: AFP, alpha-fetoprotein; CRPH, clinically relevant portal hypertension; DCD, donor after circulatory death; LDLT, living donor liver transplantation; MELD, model for end-stage liver disease; PIVKA-II, protein induced by vitamin-K absence-II; TACE, transarterial chemoembolization.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Garuti F, Neri A, Avanzato F, Gramenzi A, Rampoldi D, Rucci P, et al. . The changing scenario of hepatocellular carcinoma in Italy: An update. Liver Int. 2021;41:585–97. - PubMed
    1. Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, et al. . Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: The ITA.LI.CA database. Gut. 2023;72:141–52. - PubMed
    1. Chung RT. A watershed moment in the treatment of hepatitis C. N Engl J Med. 2012;366:273–5. - PubMed
    1. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. . Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896–904. - PubMed
    1. Del Poggio P, Olmi S, Ciccarese F, Di Marco M, Rapaccini GL, Benvegnù L, et al. . Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2014;12:1927–33.e2. - PubMed